The primary goal of the trial is to measure the decrease in the Positive and Negative Syndrome Scale from baseline.

According to the World Health Organization (WHO), over 22% of the global population smokes, with more than 9 million ...

The administration expanded the use of Pluvicto (drug name lutetium Lu 177 vipivotide tetraxetan) — for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been ...

Further investigation in HG/F-induced H9C2 cells indicated that A-MG inhibits the uptake of fatty acids (FAs) by regulating the AKT/FOXO1/CD36 signaling pathway, reduces excessive β-oxidation of FAs ...

Division of Cardiology, Department of Medicine, University of California, Los Angeles (H.M.S., K.E.J., T.Q.d.A.V., E.J.T.). Division of Cardiology, Department of ...

Mechanistically, ORM2 effects were mediated by an inositol 1,4,5-trisphosphate receptor type 2-dependent calcium pathway. Conclusion This study reveals a paracrine communication circuit during ...

These treatments can damage the hypothalamus, disrupting the MC4R pathway. By binding to and activating the MC4 receptor, Rhythm’s engineered peptide is intended to restore signaling in this ...

Obesity was linked to reduced long-term effectiveness of biologic therapy in patients with severe plaque psoriasis in a study, with dysregulated innate immune responses contributing to treatment ...

who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of drugs used in the treatment of metastatic prostate cancer. Pluvicto first got FDA approval on March 23 ...